top of page

Rachel Haurwitz on allo CAR-T at #JPM23

Caribou Biosciences's CEO Rachel Haurwitz talks about her company's allogeneic CD19 CAR-T program that has a PD-1 knockout.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page